Leishmaniasis is regarded as a neglected tropical disease by World Health Organization
(WHO) and is ranked next to malaria as the deadliest protozoan disease. The primary …

The mechanistic (or mammalian) target of rapamycin (mTOR) is considered as a critical
regulatory enzyme involved in essential signaling pathways affecting cell growth, cell …

Protozoan infections (eg, malaria, trypanosomiasis, and toxoplasmosis) pose a considerable
global burden on public health and socioeconomic problems, leading to high rates of …

The protozoan parasite Leishmania donovani (L. donovani) causes visceral leishmaniasis, a
chronic infection which is fatal when untreated. Herein, we investigated whether in addition …

Cutaneous leishmaniasis (CL), caused by protozoan parasites of the Leishmania genus, is
prevalent in tropical and subtropical regions, with important morbidity, particularly in low-to …

Leishmania, a protozoan parasite inflicting the complex of diseases called Leishmaniases,
resides and replicates as amastigotes within mammalian macrophages. As macrophages …

Leishmaniasis is an enigmatic disease that has very restricted options for chemotherapy and
none for prophylaxis. As a result, deriving therapeutic principles for curing the disease has …

Intracellular protozoan parasites are the etiologic agents of important human diseases, like
malaria, Chagas disease, toxoplasmosis, and leishmaniasis. Inside host cells, these …

Glucantime™ is the pentavalent antimony (Sb+ 5) recommended as the first choice for
treating cutaneous leishmaniasis (CL). It has been used as treatment control in animal …

Leishmaniasis is an exemplary paradigm of immune evasion, fraught with the perils of
limited clinical assistance, escalating costs of treatment and made worse with the lack of …